Stage IV Left Adrenal Carcinoma: Systemic Treatment Recommendation
For stage IV adrenocortical carcinoma, initiate first-line treatment with EDP-M (etoposide, doxorubicin, cisplatin plus mitotane) chemotherapy, unless the patient has low tumor burden and indolent disease, in which case mitotane monotherapy is appropriate with the plan to add EDP chemotherapy at progression 1.
Treatment Algorithm Based on Disease Characteristics
High Tumor Burden or Aggressive Disease
- Start EDP-M combination immediately as first-line therapy 1
- This recommendation is based on the FIRM-ACT phase III trial (304 patients) showing superior progression-free survival of 5.5 months with EDP-M versus 2.1 months with streptozotocin-mitotane 1, 2
- EDP-M is the only regimen with Level I, Grade A evidence in this setting 1
Low Tumor Burden or Indolent Disease
- Begin with mitotane monotherapy 1
- Appropriate for patients with favorable prognostic parameters (low GRAS score: better tumor Grade, complete Resection, younger Age, fewer Symptoms) 1
- Add EDP chemotherapy at disease progression 1
- The latency for mitotane to reach therapeutic range (14-20 mg/L) justifies this approach in non-urgent cases 1
Critical Mitotane Management Details
Mitotane requires meticulous monitoring:
- Target serum levels: 14-20 mg/L (therapeutic window 8-25 mg/mL) 2
- Measure levels monthly at minimum 2
- Mandatory glucocorticoid replacement: hydrocortisone 50-100 mg/day due to adrenolytic effects 2
- Higher doses (80-100 mg/day) often needed due to mitotane's enzymatic induction 2
Role of Local Therapies in Stage IV Disease
Do not overlook locoregional treatments even in metastatic disease:
- Surgery for oligometastatic disease (≤5 metastases or lesions <3 cm) significantly improves outcomes 3
- Consider surgical resection after good response to systemic therapy 1, 4
- Radiation therapy, radiofrequency ablation, and chemoembolization are valuable for accessible lesions 1, 4
- A retrospective study showed improved progression-free survival when surgical removal of residual tumor followed EDP-M compared to chemotherapy alone 2
Second-Line Options After EDP-M Failure
When first-line therapy fails, evidence is limited but emerging data supports:
- Immunotherapy combinations: PD(L)1 inhibitor plus TKI/VEGF inhibitor, or dual checkpoint blockade (PD1/CTLA-4) 5, 6
- Streptozotocin plus mitotane (objective response <10%, PFS <4 months) 2
- Gemcitabine/capecitabine ± mitotane (objective response <10%, PFS <4 months) 2
- Temozolomide showed PFS of 3.5 months in heavily pretreated patients 2
Common Pitfalls to Avoid
- Starting mitotane monotherapy in rapidly progressive disease - The 2-3 month delay to therapeutic levels can allow significant tumor progression
- Inadequate glucocorticoid replacement - Leads to adrenal crisis; don't use standard replacement doses
- Dismissing surgery in stage IV disease - Selected patients with oligometastatic disease benefit significantly from complete resection
- Failing to measure mitotane levels monthly - Narrow therapeutic window requires vigilant monitoring
- Not considering local therapies - Radiation, ablation, and embolization can provide meaningful disease control even with systemic therapy
Prognostic Considerations
The modified ENSAT staging and GRAS parameters help stratify risk 1:
- GRAS factors: tumor Grade (Ki-67), Resection status, Age, Symptoms
- Patients with resectable oligometastatic disease and long disease-free intervals have better outcomes 1
- 5-year overall survival in stage IV is <15%, but considerable heterogeneity exists 1
Clinical trials should always be preferred when available 5, given the limited efficacy of current standard therapies and the aggressive nature of this malignancy.